Xeris Biopharma HoldingsXERS
About: Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome. The Company also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect.
Employees: 377
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
361% more call options, than puts
Call options by funds: $932K | Put options by funds: $202K
43% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 37
0% more funds holding in top 10
Funds holding in top 10: 2 [Q1] → 2 (+0) [Q2]
0% less capital invested
Capital invested by funds: $137M [Q1] → $137M (-$680K) [Q2]
3.27% less ownership
Funds ownership: 44.21% [Q1] → 40.93% (-3.27%) [Q2]
6% less funds holding
Funds holding: 142 [Q1] → 134 (-8) [Q2]
33% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 24
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
HC Wainwright & Co. Oren Livnat 37% 1-year accuracy 11 / 30 met price target | 114%upside $6 | Buy Reiterated | 15 Aug 2024 |